The question of the use of Andexxa, a reversal agent for Factor Xa Inhibitors, has been batting around my brain for a few months now. We are in the unfortunate position of having a drug with very questionable evidentiary support but with an FDA labelled indication. I received an email from the lead author of paper just published in Neurocritical Care.
- Peled et al. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 10.1007/s12028-019-00866-6
I would love to hear your thoughts on this issue–place them in the comments below.
Now on to the Podcast…
Latest posts by Scott Weingart (see all)
- EMCrit Podcast 263 – The Venous Side – Part 1 – VEXUS Score with Phillipe Rola - January 14, 2020
- EMCrit 262 – Midlines – Part 1 - December 27, 2019
- EMCrit 261 – Thrombolysis during Cardiac Arrest - December 12, 2019